NAA10 Antibody

Code CSB-PA001984GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
NAA10
Alternative Names
Alpha N acetyltransferase 1A antibody; ARD1 antibody; ARD1 homolog N acetyltransferase (S. cerevisiae) antibody; ARD1 homolog A N acetyltransferase (S. cerevisiae) antibody; ARD1 homolog A N acetyltransferase antibody; ARD1A antibody; DXS707 antibody; MGC71248 antibody; N acetyltransferase ARD1, human homolog of antibody; N alpha acetyltransferase 10 NatA catalytic subunit antibody; N terminal acetyltransferase complex ARD1 subunit homolog A antibody; N(alpha) acetyltransferase 10 NatA catalytic subunit antibody; N-alpha-acetyltransferase 10 antibody; N-terminal acetyltransferase complex ARD1 subunit homolog A antibody; Naa10 antibody; NAA10_HUMAN antibody; NatA catalytic subunit antibody; TE2 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Human ARD1A
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB,IHC,IF
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Catalytic subunit of N-terminal acetyltransferase complexes which display alpha (N-terminal) acetyltransferase activity. Acetylates amino termini that are devoid of initiator methionine. The alpha (N-terminal) acetyltransferase activity may be important for vascular, hematopoietic and neuronal growth and development. Without NAA15, displays epsilon (internal) acetyltransferase activity towards HIF1A, thereby promoting its degradation. Represses MYLK kinase activity by acetylation, and thus represses tumor cell migration. Acetylates, and stabilizes TSC2, thereby repressing mTOR activity and suppressing cancer development. Acetylates HSPA1A and HSPA1B at 'Lys-77' which enhances its chaperone activity and leads to preferential binding to co-chaperone HOPX. Acetylates HIST1H4A. Acts as a negative regulator of sister chromatid cohesion during mitosis.
Gene References into Functions
  1. Since the FIH-1 dependent hydroxylation of NAA10 occurs oxygen-dependently, NAA10 acetylates HIF-1alpha under normoxia but does not under hypoxia. PMID: 30237125
  2. In combination with acetylation assays, the HypK N-terminal region is identified as a negative regulator of the NatA acetylation activity PMID: 28585574
  3. ARD1-mediated Hsp70 acetylation is a regulatory mechanism that temporally balances protein refolding/degradation in response to stress PMID: 27708256
  4. Negative regulation of Naa10 towards NTN1 and its receptor UNC5B were also detected upon treatment of all-trans retinoid acid, which was often used to induce morphological differentiation. PMID: 27910960
  5. A novel de novo NAA10 c.332 T>G p.(Val111Gly) missense variant was detected in a girl with mild/moderate non-syndromic intellectual disability. NAA10 V111G displayed reduced monomeric NAT activity and stability, but intact NatA-mediated NAT activity. PMID: 29558889
  6. Expression of ARD1 increases levels of androgen receptor acetylation and androgen receptor-HSP90 dissociation in a dose dependent manner. PMID: 27659526
  7. Study reports on a total of 12 affected females with four different de novo missense mutations in NAA10 and one inherited mutation in a familial case due to germline mosaicism, thus further expanding themutational and clinical spectrum associated with NAA10 related N-terminal-acetyltransferase deficiency. PMID: 27094817
  8. our study illustrated that the expression of Naa10p had a potential value for predicting the progression of OSCC and prognosis of OSCC patients. PMID: 26662107
  9. The results observed an inverse correlation between the expression of NAA10 and that of miR-342-5p and miR-608 . PMID: 26646451
  10. Human Naa15 (NATH) and Naa10 (ARD1) form a stable NatA complex which associates with ribosomes and performs co-translational N-terminal acetylation; Naa15 (NATH) and Naa10 (ARD1) are cleaved during apoptosis resulting in decreased acetyltransferase activity PMID: 15496142
  11. The clinical spectrum of NAA10. PMID: 26522270
  12. there is no difference in lysine acetylation of substrate proteins with or without Naa10, suggesting that the substrates may be acetylated chemically rather than enzymatically. PMID: 26755727
  13. Combined high expression of Naa10p, SNCG and PRL-3 are associated with lymph node metastasis in breast cancer. PMID: 25854368
  14. De novo missense mutations in the NAA10 gene cause severe non-syndromic developmental delay in males and females PMID: 25099252
  15. human ARD1 variants have different effects on cell proliferation, which may result from distinct subcellular localizations and autoacetylation activities. PMID: 25421966
  16. Naa10 structure and function. [Review] PMID: 25987439
  17. Autoacetylation of ARD1 variants differentially regulates angiogenesis and cell proliferation in an isoform-specific manner. PMID: 25338643
  18. ARD1 has a crucial role in the cellular response to oxidative stress as a bona fide regulator of MSRA. PMID: 25341044
  19. Naa10p inhibits the metastasis of breast cancer cells by targeting STAT5a. PMID: 24925029
  20. results show that hARD1 nuclear translocation mediated by NLS is required for cell cycle progression, thereby contributing to proper cell proliferation. PMID: 25133627
  21. Study describes a Saccharomyces cerevisiae model developed by introducing the human wild-type (wt) or mutant NatA complex into yeast lacking NatA (NatA-Delta). The wt human NatA complex phenotypically complemented the NatA-Delta strain, whereas only a partial rescue was observed for the Ogden mutant NatA complex suggesting that hNaa10 S37P is only partially functional in vivo. PMID: 24408909
  22. The study concludes that the NAA10 mutation is the cause of Lenz microphthalmia syndrome in a family, likely through the dysregulation of the retinoic acid signalling pathway. PMID: 24431331
  23. Protein N-terminal acetyltransferases (NATs), including Naa10, act as N-terminal propionyltransferases. PMID: 23043182
  24. Development of the first specific NAT-inhibitors, including inhibitors targeting Naa10. PMID: 23557624
  25. Structural characterization of native hARD1 using size exclusion chromatography, circular dichroism, & fluorescence spectroscopy shows the protein consists of compact globular region comprising 2 thirds of the protein & a flexible unstructured C terminus. PMID: 16823041
  26. ARD1 functions as an inhibitor of the mTOR pathway and that dysregulation of the ARD1-TSC2-mTOR axis may contribute to cancer development PMID: 20145209
  27. These results indicate that ARD1A is a novel tumor-associated antigen and a potential prognostic factor for colon cancer. PMID: 20639454
  28. The expression level of NAA10 is inversely correlated with that of MMP-9 in breast cancer samples. PMID: 23550278
  29. Naa10p suppresses 28S proteasome activity through interaction with PA28beta. PMID: 23624078
  30. These data indicate that the interaction between ARD1 and RIP1 plays an important role in the DNA damage-induced NF-kappaB activation, and that the acetyltransferase activity of ARD1 and its localization in to the nucleus are involved in such stress response. PMID: 22580278
  31. study revealed a novel mechanism controlling MCL1 expression, in which Naa10p and RelA/p65 synergistically interact with MCL1 promoter region and promote MCL1 transcription PMID: 22496479
  32. Arrest-defective protein 1 homolog A (ARD1) in combination with SNCG/Hiwi/PRL-3 may lead to a poor outcome in patients with or without lymph node metastatic colon cancer. PMID: 22261620
  33. ARD1 functions as a unique AR regulator in prostate cancer cells. PMID: 22315407
  34. A reduction in acetylation by hNaa10p causes lethal X-linked disorder of infancy. PMID: 21700266
  35. N(alpha)-acetyltransferase 10 may function as a post-translational actin N(alpha)-acetyltransferase. PMID: 21383206
  36. suggest that Naa10p functions as a tumor metastasis suppressor by disrupting the migratory complex, PIX-GIT- Paxillin, in cancer cells PMID: 21295525
  37. interaction between hNaa10p and DNMT1 was required for E-cadherin silencing through promoter CpG methylation, and E-cadherin repression contributed to the oncogenic effects of hNaa10p. PMID: 20592467
  38. Results show that hARD1 autoacetylation is critical for its activation and its ability to stimulate cancer cell proliferation and tumorigenesis. PMID: 20501853
  39. Data indicate that the physical interaction between HYPK and NatA Naa10/15 seems to be of functional importance both for huntingtin aggregation and for N-terminal acetylation. PMID: 20154145
  40. hARD1 is a bona fide regulator of MLCK, and hARD1 plays a crucial role in the balance between tumor cell migration and stasis PMID: 19826488
  41. ARD1-mediated acetylation regulates and destabilizes HIF-1 alpha by directly binding to it. PMID: 12464182
  42. description of the human homologue of Nat1p, NATH (NAT human), as the binding partner of the hARD1 (human ARD1) protein PMID: 15496142
  43. Amino-terminal acetyltransferase ARD1 (hARD1) interacts with a novel motif, 658-HGVVEVD-664, in the cytoplasmic domain of beta-amyloid precursor protein. PMID: 15749829
  44. ARD1 is involved in cell proliferation and in regulating a series of cellular metabolic pathways that are regulated during hypoxia response. PMID: 15755738
  45. Data demonstrate that ARD1 has limited, if any, impact on the HIF-1alpha signaling pathway. PMID: 15994306
  46. levels of endogenous NATH and hARD1 proteins in thyroid papillary carcinoma patients; results suggest that NATH positively affects the level of hARD1 protein both in vivo and in cell cultures PMID: 16279846
  47. ARD1 specifically binds HIF-1 alpha, suggesting a putative, still unclear, connection between these proteins. PMID: 16288748
  48. A human ARD1 variant ortholog (235) has weak effects on hypoxia inducible factor (HIF)-1 alpha and VEGF mRNA stability compared to mouse ARD1 ortholog 225. PMID: 16376303
  49. Essential role in cell survival through protein N-alpha-acetylation. PMID: 16518407
  50. These results indicate that ARD1(235) and ARD1(225) isoforms may have different activities and function in different subcellular compartments of mammalian cells. PMID: 17161380

Show More

Hide All

Involvement in disease
N-terminal acetyltransferase deficiency (NATD); Microphthalmia, syndromic, 1 (MCOPS1)
Subcellular Location
Cytoplasm. Nucleus.
Protein Families
Acetyltransferase family, ARD1 subfamily
Tissue Specificity
Ubiquitous.
Database Links

HGNC: 18704

OMIM: 300013

KEGG: hsa:8260

STRING: 9606.ENSP00000417763

UniGene: Hs.433291

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*